文献速递关节外科创伤骨科

双侧TKA中静脉联合关节腔内氨甲环酸与单用关节腔内相比无额外获益:随机对照试验

Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial.
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

该随机对照试验纳入同日或分期双侧TKA患者,比较单用关节腔内TXA与静脉联合关节腔内TXA在失血量和输血率上的差异。结果显示两组总失血量无临床重要差异,输血率和不良事件频率均低且无差异。作者推荐不要联合使用静脉和关节腔内TXA,单用关节腔内TXA对常规TKA已足够。

要点

  • 同日双侧TKA中,单用关节腔内TXA与联合静脉TXA的总失血量无显著差异(p=0.08)。
  • 分期双侧TKA中,联合组总失血量较单用组低64 mL(95%CI 1-127;p=0.046),但作者认为无临床差异。
  • 两组输血率及症状性血栓栓塞、伤口并发症、假体周围感染频率均低且无差异。

核心结论

  • 单用关节腔内TXA与静脉联合关节腔内TXA在双侧TKA中总失血量和输血率无差异。
  • 作者推荐不要联合使用静脉和关节腔内TXA,单用关节腔内TXA对常规TKA已足够。

研究设计与样本

  • 随机对照试验,2015年4月至2017年5月由一名外科医生完成316例同日双侧TKA和314例分期双侧TKA。
  • 每组98%患者符合条件并全部同意参与随机:同日TKA单用关节腔内TXA组n=157,联合组n=153;分期TKA单用组n=156,联合组n=155。
  • 主要结局为基于患者血容量和血红蛋白下降计算的总失血量及输血情况;次要结局包括术后血红蛋白下降、血红蛋白低于7.0、8.0或9.0 g/dL的比例及不良事件频率。
  • 证据等级为Level I,治疗性研究。

主要发现

  • 同日双侧TKA总失血量:单用关节腔内TXA组1063 mL ± 303 mL vs 联合组1004 mL ± 287 mL,平均差59 mL(95%CI -7至125),p=0.08。
  • 分期双侧TKA总失血量:单用组909 mL ± 283 mL vs 联合组845 mL ± 278 mL,平均差64 mL(95%CI 1至127),p=0.046。
  • 同日TKA输血率:单用组0%(0/152) vs 联合组1%,p=0.149;分期TKA输血率:单用组1%(1/155) vs 联合组0%(0/153),p=0.98。
  • 症状性深静脉血栓、症状性肺栓塞、伤口并发症和假体周围感染频率低,在现有样本量下各组间无差异。

关键数值与推荐

  • 同日双侧TKA总失血量平均差59 mL(95%CI -7至125),p=0.08。
  • 分期双侧TKA总失血量平均差64 mL(95%CI 1至127),p=0.046。
  • 同日TKA输血率单用组0%(0/152) vs 联合组1%,p=0.149;分期TKA单用组1%(1/155) vs 联合组0%(0/153),p=0.98。
  • 作者推荐:不要联合使用静脉和关节腔内TXA;单用关节腔内TXA对常规TKA已足够。

临床怎么用

  • 对于双侧TKA患者,单用关节腔内TXA即可,无需联合静脉TXA。
  • 联合静脉和关节腔内TXA未显示额外减少失血或输血的优势。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) is efficacious for reducing blood loss and transfusion use in patients who undergo bilateral TKA, and it is administered intravenously alone, intraarticularly alone, or as a combination of these. However, it is unclear whether combined intravenous (IV) and intraarticular TXA offers any additional benefit over intraarticular use alone in patients undergoing bilateral TKA. QUESTIONS/PURPOSES: The purposes of our study was to determine (1) whether combined IV and intraarticular TXA reduces blood loss and blood transfusion use compared with intraarticular use alone and (2) whether the frequency of adverse events is different between these routes of administration in patients who undergo simultaneous or staged bilateral TKA. METHODS: Between April 2015 and May 2017, one surgeon performed 316 same-day bilateral TKAs and 314 staged bilateral TKAs. Of those, 98% of patients in each same-day TKA (310) and staged bilateral TKA (309) groups were eligible for this randomized trial and all of those patients agreed to participate and were randomized. The study included four groups: simultaneous TKA with intraarticular TXA only (n = 157), simultaneous TKA with IV and intraarticular TXA (n = 153), staged TKA with intraarticular TXA only (n = 156), and staged TKA with IV and intraarticular TXA (n = 155). There were no differences in demographic data among the intraarticular alone and IV plus intraarticular TXA groups of patients who underwent simultaneous or staged bilateral TKA in terms of age, proportion of female patients, BMI, or preoperative hematologic values. The primary outcome variables were total blood loss calculated based on patient blood volume and a drop in the hemoglobin level and administration of blood transfusion. The secondary outcomes of this study were a decrease in the postoperative hemoglobin level; the proportion of patients with a hemoglobin level lower than 7.0, 8.0, or 9.0 g/dL; and the frequencies of symptomatic deep vein thrombosis, symptomatic pulmonary embolism, wound complications, and periprosthetic joint infection. RESULTS: Total blood loss with intraarticular TXA alone in patients undergoing simultaneous bilateral TKA and those undergoing staged procedures was not different from the total blood loss with the combined IV plus intraarticular TXA regimen (1063 mL ± 303 mL versus 1004 mL ± 287 mL, mean difference 59 mL [95% CI -7 to 125]; p = 0.08 and 909 ml ± 283 ml versus 845 ml ± 278 ml; mean difference 64 mL [95% CI 1 to 127]; p = 0.046, respectively). The use of blood transfusions between intraarticular alone and combined IV and intraarticular TXA was also not different among patients undergoing simultaneous (0% [0 of 152] versus 1%; p = 0.149) and staged TKA (1% [1 of 155] versus 0% [0 of 153]; p = 0.98). Furthermore, the frequency of symptomatic thromboembolic events, wound complications, and periprosthetic joint infections was low, without any differences among the groups with the numbers available. CONCLUSION: Because there was no difference between intraarticular alone and combined intraarticular plus IV regimen of TXA administration, we recommend that IV and intraarticular TXA should not be used in combination. Moreover, other studies have found no differences between intraarticular and IV TXA used alone, and hence to avoid potential complications associated with systemic administration, we recommend that intraarticular alone is sufficient for routine TKA. LEVEL OF EVIDENCE: Level I, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Meshram P, Palanisamy JV, Seo JY, et al. Combined Intravenous and Intraarticular Tranexamic Acid Does Not Offer Additional Benefit Compared with Intraarticular Use Alone in Bilateral TKA: A Randomized Controlled Trial. Clin Orthop Relat Res. 2020. PMID: 31498264. doi:10.1097/CORR.0000000000000942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。